HCRT and Parkinson disease: Inflammatory pathways, neurotransmitter dysregulation—particularly involving orexin—and neuroimmune activation have been implicated in the pathogenesis of Parkinson’s disease [51] and AD [52], suggesting similar mechanisms may contribute to ET-related neurodegeneration.